{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:45:20Z","timestamp":1783381520342,"version":"3.54.6"},"reference-count":53,"publisher":"SLACK, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Ann"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>\n            The interleukin (IL) -1 family of cytokines are involved in different aspects of inflammation with IL-1 beta being the best known and most powerful proinflammatory cytokine. Dysregulation of IL-1 beta and other family members results in autoinflammatory conditions such as systemic juvenile idiopathic arthritis and familial Mediterranean fever. The growing understanding and knowledge of the pathophysiology of many autoinflammatory diseases have led to the development and use of IL-1 blocking medications for many chronic and disabling diseases. In this article, we present the anti\u2013IL-1 agents and their major indications in pediatric rheumatology.\n            <jats:bold>\n              [\n              <jats:italic>Pediatr Ann<\/jats:italic>\n              . 2022;51(2):e72\u2013e76.]\n            <\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/19382359-20220115-01","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T14:38:39Z","timestamp":1644849519000},"source":"Crossref","is-referenced-by-count":2,"title":["The Role of Anti\u2013IL-1 Medications in Autoinflammatory Disease"],"prefix":"10.3928","volume":"51","author":[{"given":"Rotem","family":"Semo-Oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar","family":"Biton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S.","family":"Tesher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-016-0559-z"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.012"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12621"},{"key":"e_1_3_1_5_2","first-page":"621","article-title":"Masters, Anna Simon, Ivona Aksentijevich, and Daniel L. Kastner, Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease IL-1 and related cytokines in innate and adaptive immunity in health and disease","volume":"27","author":"Seth L","year":"2009","unstructured":"Seth L. Masters, Anna Simon, Ivona Aksentijevich, and Daniel L. Kastner, Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease IL-1 and related cytokines in innate and adaptive immunity in health and disease. Annu Rev Immunol. 2009;27:621\u2013668.","journal-title":"Annu Rev Immunol"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.10.001"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12606"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807865"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0277-8"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081898"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01412"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40055"},{"key":"e_1_3_1_13_2","unstructured":"US Food and Drug Administration. Anakinra. Accessed January 15 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl.pdf"},{"key":"e_1_3_1_14_2","unstructured":"European Medicines Agency. Anakinra . Accessed January 15 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kineret-epar-product-information_en.pdf"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3293-2"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41481"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa112"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-7-21"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619257"},{"key":"e_1_3_1_20_2","unstructured":"European Medicines Agency. Ilaris: overview. Accessed January 15 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilaris"},{"key":"e_1_3_1_21_2","unstructured":"US Food and Drug Administration. Ilaris. Accessed January 15 2022. https:\/\/www.access-data.fda.gov\/drugsatfda_docs\/label\/2016\/BLA125319_858687lbl.pdf"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/11599820-000000000-00000"},{"key":"e_1_3_1_23_2","unstructured":"Novartis Pharmaceuticals Corporation. Highlights of prescribing information. Ilaris (canakinumab) . Accessed January 28 2022. https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/ilaris.pdf?ref=binfind.com\/web#:\u223c:text=ILARIS%20is%20indicated%20for%20the%20treatment%20of%20Familial%20Mediterranean%20Fever in%20adult%20and%20pediatric%20patients.&text-=ILARIS%20is%20indicated%20for%20the%20treatment%20of%20active%20Still's%20disease aged%202%20years%20and%20older"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23620"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055137"},{"key":"e_1_3_1_26_2","unstructured":"US Food and Drug Administration. Rilonacept. Accessed January 15 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125249lbl.pdf"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712590902875518"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000315"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh710"},{"issue":"2","key":"e_1_3_1_30_2","first-page":"343","article-title":"Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR)","volume":"35","author":"Behrens EM","year":"2008","unstructured":"Behrens EM, Beukelman T, Gallo L. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343\u2013348. PMID:18085728","journal-title":"J Rheumatol"},{"issue":"2","key":"e_1_3_1_31_2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","unstructured":"Petty RE, Southwood TR, Manners PInternational League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u2013392. PMID:14760812","journal-title":"J Rheumatol"},{"issue":"5","key":"e_1_3_1_32_2","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens EM","year":"2007","unstructured":"Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133\u20131138. PMID:17343315","journal-title":"J Rheumatol"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050473"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.619273"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.004"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170259"},{"issue":"2","key":"e_1_3_1_37_2","first-page":"491","article-title":"Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years","volume":"27","author":"Lomater C","year":"2000","unstructured":"Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491\u2013496. PMID:10685819","journal-title":"J Rheumatol"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23437"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38092"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21625"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38296"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21889"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41073"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheum-dis-2019-216040"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24458"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00253"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1162261"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1201-7"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010128"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209686"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34409"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1702946114"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093263"}],"container-title":["Pediatric Annals"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:55:39Z","timestamp":1683075339000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/19382359-20220115-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.3928\/19382359-20220115-01"],"URL":"https:\/\/doi.org\/10.3928\/19382359-20220115-01","relation":{},"ISSN":["0090-4481","1938-2359"],"issn-type":[{"value":"0090-4481","type":"print"},{"value":"1938-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}